X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs NATCO PHARMA - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA NATCO PHARMA AUROBINDO PHARMA/
NATCO PHARMA
 
P/E (TTM) x 14.7 19.9 74.1% View Chart
P/BV x 3.8 19.0 20.0% View Chart
Dividend Yield % 0.4 0.6 68.3%  

Financials

 AUROBINDO PHARMA   NATCO PHARMA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-17
NATCO PHARMA
Mar-14
AUROBINDO PHARMA/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs895877 102.1%   
Low Rs622424 146.9%   
Sales per share (Unadj.) Rs254.6223.4 113.9%  
Earnings per share (Unadj.) Rs39.331.1 126.4%  
Cash flow per share (Unadj.) Rs46.640.3 115.7%  
Dividends per share (Unadj.) Rs2.505.00 50.0%  
Dividend yield (eoy) %0.30.8 42.9%  
Book value per share (Unadj.) Rs160.0219.5 72.9%  
Shares outstanding (eoy) m585.8833.07 1,771.6%   
Bonus/Rights/Conversions ESOPPA-  
Price / Sales ratio x3.02.9 102.4%   
Avg P/E ratio x19.320.9 92.3%  
P/CF ratio (eoy) x16.316.1 100.9%  
Price / Book Value ratio x4.73.0 160.1%  
Dividend payout %6.416.1 39.5%   
Avg Mkt Cap Rs m444,39021,504 2,066.6%   
No. of employees `00014.0NA-   
Total wages/salary Rs m17,6781,128 1,567.6%   
Avg. sales/employee Rs Th10,667.8NM-  
Avg. wages/employee Rs Th1,264.3NM-  
Avg. net profit/employee Rs Th1,645.8NM-  
INCOME DATA
Net Sales Rs m149,1577,389 2,018.7%  
Other income Rs m1,159167 693.5%   
Total revenues Rs m150,3167,556 1,989.4%   
Gross profit Rs m34,3431,793 1,915.1%  
Depreciation Rs m4,276304 1,404.8%   
Interest Rs m667366 182.2%   
Profit before tax Rs m30,5581,290 2,369.2%   
Minority Interest Rs m5046 108.4%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7,597309 2,460.8%   
Profit after tax Rs m23,0121,027 2,239.8%  
Gross profit margin %23.024.3 94.9%  
Effective tax rate %24.923.9 103.9%   
Net profit margin %15.413.9 111.0%  
BALANCE SHEET DATA
Current assets Rs m92,0623,681 2,500.8%   
Current liabilities Rs m66,2233,123 2,120.6%   
Net working cap to sales %17.37.6 229.2%  
Current ratio x1.41.2 117.9%  
Inventory Days Days10689 118.4%  
Debtors Days Days6859 115.3%  
Net fixed assets Rs m62,9197,685 818.7%   
Share capital Rs m586331 177.2%   
"Free" reserves Rs m93,1336,670 1,396.3%   
Net worth Rs m93,7197,259 1,291.1%   
Long term debt Rs m1,814955 190.0%   
Total assets Rs m162,49411,957 1,359.0%  
Interest coverage x46.84.5 1,034.9%   
Debt to equity ratio x00.1 14.7%  
Sales to assets ratio x0.90.6 148.5%   
Return on assets %14.611.7 125.0%  
Return on equity %24.614.2 173.5%  
Return on capital %32.720.7 158.0%  
Exports to sales %039.4 0.0%   
Imports to sales %05.7 0.0%   
Exports (fob) Rs mNA2,908 0.0%   
Imports (cif) Rs mNA421 0.0%   
Fx inflow Rs m75,8383,445 2,201.1%   
Fx outflow Rs m30,224703 4,300.6%   
Net fx Rs m45,6132,743 1,663.1%   
CASH FLOW
From Operations Rs m32,7861,440 2,276.3%  
From Investments Rs m-17,870-1,089 1,640.7%  
From Financial Activity Rs m-19,153-353 5,430.3%  
Net Cashflow Rs m-4,239-1 284,476.5%  

Share Holding

Indian Promoters % 54.1 52.0 104.0%  
Foreign collaborators % 0.0 1.5 -  
Indian inst/Mut Fund % 8.0 7.8 101.4%  
FIIs % 27.7 16.6 166.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 26.0 39.2%  
Shareholders   69,601 25,395 274.1%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   DIVIS LABORATORIES  WOCKHARDT LTD.  VENUS REMEDIES  PLETHICO PHARMA  GLENMARK PHARMA  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 262 Points Lower; Metal & Realty Stocks Fall(Closing)

Indian share markets ended lower today amid weak global cues. At the closing bell, the BSE Sensex finished lower by 262 points.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 0.4%

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, AUROBINDO PHARMA has posted a net profit of Rs 5 bn (down 0.4% YoY). Sales on the other hand came in at Rs 40 bn (up 11.2% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 69.6%

May 25, 2018 | Updated on May 25, 2018

For the quarter ended March 2018, NATCO PHARMA has posted a net profit of Rs 3 bn (up 69.6% YoY). Sales on the other hand came in at Rs 8 bn (up 32.9% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jun 19, 2018 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS